1991 INDEX

A

Abscess
  liver, in inflammatory bowel disease, Nov., 704
  lung, *Pseudomonas aeruginosa*, May, 287
Acetylcholine release: inhibition by tetanospasmin, Sept., 573
Acetyl cysteine: in asthma, Jan., 43
Addicts: narcotic, severity of tetanus in, Sept., 576
Adenocarcinoma: in inflammatory bowel disease, Nov., 701
Adenoma: prolactin/growth hormone-producing pituitary, somatostatin and octreotide in, Dec., 785
ADH secretion: inappropriate, in tetanus, Sept., 574
Adrenal androgen hormone synthesis: hypothalamic pituitary regulation of, Apr., 251
Adrenalectomy: in prostate cancer, Apr., 252
Adrenalin-like bronchodilators: in asthma, Jan., 31
Aerobid: in asthma, Jan., 35
Age
  prostate cancer and, Apr., 209
  pulmonary nodules and, solitary, May, 293
  -specific death rates from asthma, Mar., 151
Air: cold air challenge in asthma, Mar., 171
Airflow obstruction
  in asthma, Mar., 160–162
  in Wegener's granulomatosis, Feb., 106
Airway
  control in tetanus, Sept., 588
  pressure
    constant distending, traditional systems for generating, June, 358–363
    continuous positive (*see* CPAP) release ventilation, June, 365
Alarms: ventilator, June, 366–367
Albuterol in asthma, Jan., 15
  powder preparation, Jan., 34
Alcohol: and asthma, Jan., 23
Alginate pulmonary hypersensitivity, July, 457–458
Alimentation: elemental, in Crohn's disease, Nov., 723
Allergic
  alveolitis, extrinsic, differences between sarcoidosis and, July, 442
  bronchopulmonary aspergillosis, Mar., 153, 155
Allescheriasis: presenting as solitary pulmonary nodule, May, 286
Alpha adrenergic blockers: in asthma, Jan., 43–44
Alpha-tocopherylquinone: in ulcerative colitis, Nov., 724
Alupent: in asthma, Jan., 15
Alveolar
  (*See also* Intraalveolar)
  bronchoalveolar lavage (*see* Bronchoalveolar lavage)
  hemorrhage syndrome, diffuse, diseases causing, Feb., 113
  proteinosis, pulmonary (*see* Proteinosis, pulmonary alveolar)
Alveolitis
  allergic, extrinsic, differences between sarcoidosis and, July, 442
  mechanism in hypersensitivity pneumonitis, July, 429
Alzheimer's disease: somatostatin levels in, Dec., 796
Amino acid sequence: of tetanospasmin, Sept., 567

Aminophylline: in asthma, Jan., 16–17
5-Aminosalicylic acid: in inflammatory bowel disease, Nov., 716–717
Amyloidosis: pulmonary, May, 289
Analgesia: somatostatin and octreotide for, Dec., 793–794
Anaphylactoid responses: to tetanus toxoid, Sept., 594
Anatomy: prostate, Apr., 213–214
Androgen(s)
  ablation, total, in prostate cancer, Apr., 254
  circulation, removal of primary source of, in prostate cancer, Apr., 252
  deprivation methods in prostate cancer, Apr., 251–253
  hormone synthesis, adrenal, hypothalamic pituitary regulation of, Apr., 251
Anesthesia: epidural, in tetanus, Sept., 590
Aneurysms: pulmonary arteriovenous, MRI of, May, 295
Angiogenesis: effect of somatostatin and octreotide on, Dec., 788
Angiography: pulmonary, in solitary pulmonary nodules, May, 294
Angiotensin converting enzyme inhibitors: and bronchial hyperreactivity, Mar., 153
Animals: inflammatory bowel disease in, Oct., 632–634
Antibacterial drugs: in inflammatory bowel disease, Nov., 717–720
Antibiotic(s)
  -associated colitis, Nov., 709–710
  in asthma, Jan., 19
  in tetanus, Sept., 588
  in Wegener's granulomatosis, Feb., 108
Antibody(ies)
  anticytoplasmic, in Wegener's granulomatosis, Feb., 106–107
  -antigen complexes in inflammatory bowel disease, Oct., 639–640
Anticholinergic drugs in asthma, Mar., 177
  chronic, Jan., 36–37
  severe, Jan., 17; Mar., 185
Anticytoplasmic antibodies: in Wegener's granulomatosis, Feb., 106–107
Antidepressants: in inflammatory bowel disease, Nov., 715–717
Antidiarrheal medication: in inflammatory bowel disease, Nov., 714–715
Antidiuretic hormone secretion: inappropriate, in tetanus, Sept., 574
Antigen
  -antibody complexes in inflammatory bowel disease, Oct., 639–640
  cockroach, as cause of asthma, Jan., 22
  DF3, in inflammatory bowel disease, Oct., 629
  HLA, in inflammatory bowel disease, Oct., 647
  P1 erythrocyte, in hypersensitivity pneumonitis, July, 421
  prostate specific (*see* Prostate, specific antigen)
Antigenic
  material in hypersensitivity pneumonitis, nature of, July, 421
  particle size in hypersensitivity pneumonitis, July, 422
Antihistamines: in asthma, Jan., 37; Mar., 179
Anti-inflammatory agents
  in asthma, Jan., 45–49; Mar., 177–179
  inflammatory bowel disease due to, in elderly, Nov., 794
Antispasmodic medication: in inflammatory bowel disease, Nov., 714–715
Antispasticity agents: in tetanus, Sept., 589–590

Antitetanus immune status: determination of, Sept., 584
Apheresis: T lymphocyte, in inflammatory bowel disease, Nov., 721
Arachidonic acid: in inflammatory bowel disease, Oct., 630
Arteriovenous aneurysms: pulmonary, MRI of, May, 295
Artery(ies)
  blood gases in asthma, Jan., 14; Mar., 166
  blood pressure (*see* Blood, pressure measurement, systemic arterial)
  cannulation technique with Swan-Ganz catheter, Aug., 527, 529
  hepatic, blood flow, effect of somatostatin and octreotide on, Dec., 763
  pulmonary (*see* Pulmonary, artery)
Arthritis
  of inflammatory bowel disease, Nov., 704
  rheumatoid (*see* Rheumatoid arthritis)
5-ASA: in inflammatory bowel disease, Nov., 716–717
Ascaricides: and asthma, Jan., 21
Ascites: pancreatic, somatostatin in, Dec., 773–774
Aspergillosis: allergic bronchopulmonary, Mar., 153, 155
Aspiration biopsy: transthoracic needle, of solitary pulmonary nodules, May, 301–302
Aspirin-induced asthma, Jan., 23–24
Astemizole: in asthma, Jan., 37
Asthma. Jan., 11–58; Mar., 149–196
  acute
    prevention, Mar., 180–183
    treatment, Jan., 12–20; Mar., 183–186
  airflow obstruction in, Mar., 160–162
  alpha adrenergic blockers in, Jan., 43–44
  antibiotics in, Jan., 19
  anticholinergic agents in, Jan., 17, 36–37
  anti-inflammatory agents in, Jan., 45–49; Mar., 177–179
  beta-adrenergic agonists in (*see* Beta-adrenergic agonists in asthma)
  blood gases in, arterial, Jan., 14; Mar., 166
  bronchial (*see* Asthma)
  bronchial hyperresponsiveness in, Mar., 159–160
  bronchial provocation testing in, Mar., 170–171
  bronchodilators in, Jan., 31; Mar., 172–177
  calcium channel blockers in, Jan., 43
  cardiac monitoring in, Jan., 15
  chronic, management, Jan., 20–27
  clinical features, Mar., 162–171
  corticosteroids in (*see* Corticosteroids, in asthma)
  course, Mar., 188–190
  cromolyn sodium in, Jan., 34
  deaths, Mar., 150
    age-specific, Mar., 151
  definition, Mar., 149
  drug therapy in, Jan., 11–58; Mar., 172–179
    chronic, Jan., 27–44
    in-hospital modification of, Jan., 19–20
    preventive, Mar., 181–183
    supplemental, Jan., 42
    unusual, Jan., 45–49
  in elderly, Mar., 188
  FEV_1 decrease in, Mar., 170
  fluids in, intravenous, Jan., 14–15
  gamma globulin in, IV, Jan., 47–48
  gastroesophageal reflux and, Jan., 25
  gold in, Jan., 47

Asthma *(cont.)*
H_1 receptor antagonists in, Jan., 37
hormonal influences in, Jan., 25–26
hospitalization for, Jan., 19
immunotherapy in, Jan., 48–49; Mar., 180–181
inhaler in, metered dose, recommended procedures for optimum use, Mar., 174
ketotifen in, Jan., 37–38
laboratory tests in, Mar., 167–168
management, Mar., 172
management after acute attack, Mar., 186–187
methotrexate in, Jan., 46
nedocromil in, Jan., 38
neural mechanisms in, Mar., 160
nocturnal
causes, Jan., 27
treatment, Jan., 26–27; Mar., 187
occupational, Jan., 24–25; Mar., 153
causes, Mar., 154
oxygen in, Jan., 14
pathophysiology, Mar., 155–162
pharmacotherapy in *(see* drug therapy in *above)*
physical therapy in, Jan., 15
potassium chloride in, Jan., 18
potassium iodide in, Jan., 42–43
in pregnancy, treatment, Jan., 44; Mar., 187–188
prevention, avoidance of precipitating factors in, Mar., 180
prognosis, Mar., 188–190
provoking agents in, determination of, Mar., 171
psychological factors in, Jan., 26
pulmonary function tests in, Jan., 14; Mar., 164–166
sedation in, Jan., 15
severe *(see* acute *above)*
severity
assessment, Mar., 168–169
grading of, Mar., 163
signs, Mar., 162–164
sinusitis and, Jan., 24
sodium bicarbonate in, Jan., 18
sympathomimetics in, Jan., 15–16
symptoms, Mar., 162–164
syndrome
classification, Mar., 152–155
definition, Mar., 149
theophylline in *(see* Theophylline in asthma)
triggering, factors in, Jan., 22
troleandomycin in, Jan., 45–46
ventilation in, mechanical, Jan., 20
viral infection and, Jan., 24
x-rays in, chest, Jan., 14; Mar., 166–167
Asthmatic
bronchitis, Mar., 153
response
acute, Mar., 157–158
acute, features of, Mar., 157
acute, relation to late response and to bronchial hyperreactivity, Mar., 158
late, Mar., 158–159
late, features of, Mar., 157
late, mediators associated with, Mar., 159
late, relation to acute response and to bronchial hyperreactivity, Mar., 158
Atracurium: in tetanus, Sept., 590
Atrial pressure: left, and Swan-Ganz catheter location, Aug., 522–523
Atropine
in asthma, Mar., 177
methonitrate in asthma, Jan., 37
sulfate in asthma
chronic, Jan., 36–37
severe, Jan., 17
Atrovent: in asthma, Jan., 36–37
Auranofin: in asthma, Jan., 47
Autoimmunity: in inflammatory bowel disease, Oct., 642–643
Autonomic
nervous system *(see* Nervous system, autonomic)

neuropathy and hypotension, somatostatin and octreotide in, Dec., 794
Auto-PEEP: during mechanical ventilation, June, 401–402
Azathioprine
in inflammatory bowel disease, Nov., 720–721
in pulmonary fibrosis, idiopathic, Feb., 80–81
Azmacort, Jan., 35

B

Baclofen: in tetanus, Sept., 589
Bactrim (*see* Trimethoprim-sulfamethoxazole)
Bagassosis, July, 445–446
Beclomethasone dipropionate
in asthma, Jan., 35; Mar., 179
in inflammatory bowel disease, Nov., 720
Beclovent: in asthma, Jan., 35
Behavioral
abnormalities and theophylline, Jan., 29
disorders, tetanospasmin in study of, Sept., 575
effects of somatostatin and octreotide, Dec., 795–796
Bell: Sir Charles Bell's sketch of soldier with tetanus, Sept., 560
Bennett MA-1 ventilator, June, 369–381
alarm(s)
cascade humidifier, June, 381
spirometer, June, 380–381
assist-control mode, June, 374
assistor functions, June, 373
control(s), June, 374–379
basic, June, 374
expiratory resistance, June, 378
function, June, 374–379
identification, June, 374–379
manual switch, June, 379
nebulizer, June, 378–379
normal pressure limit, June, 375–376
normal volume, June, 376
on/off switch, June, 375
oxygen percentage, June, 378
panel, June, 375
peak flow, June, 374–375
respiratory rate, June, 376–377
sensitivity, June, 374
sigh pressure limit, June, 377
sigh volume, June, 377
sighs per hour, June, 377
as constant-flow generator, June, 373
controller functions, June, 374
double-circuit system, June, 372–373
electrically powered, June, 370
gas flow through, schematic, June, 371
light(s)
assist, June, 379
oxygen, June, 380
pressure, June, 379
ratio, June, 379–380
sigh, June, 380
monitoring, June, 379–381
operating, June, 379–381
rear panel exposed, June, 372
volume-cycled, June, 370, 372
Bennett 7200 ventilator
control panel for, June, 395
respiratory flow wave patterns, June, 390
schematic, June, 389
technical data and specifications for, June, 391–394
Benzodiazepines: in tetanus, Sept., 589
Bernard, Claude, Sept., 562
Berylliosis, July, 458
Beta-adrenergic agonists in asthma, Jan., 30–34; Mar., 172–175
acute, Mar., 183–184
adverse effects, Jan., 32–34
commercially available, in U.S., Mar., 184
Beverages: and asthma attacks, Mar., 180
Bicarbonate: sodium, in asthma, Jan., 18

Biliary abnormalities: in inflammatory bowel disease, Nov., 702–703
Biopsy
bronchoscopic, of solitary pulmonary nodules, May, 300–301
extrathoracic, in interstitial lung disease, Feb., 126
lung
aspiration, transthoracic needle, of solitary pulmonary nodules, May, 301–302
open, in idiopathic pulmonary fibrosis, Feb., 75, 76
open, in interstitial lung disease, Feb., 126
open, in pulmonary alveolar proteinosis, Feb., 117
in rheumatoid interstitial lung disease, Feb., 95
prostate, Apr., 217–218
after irradiation, external beam, Apr., 246
of pulmonary nodules, solitary, May, 300–302
Bird fancier's lung, July, 442–444
Blacks: American, prostate cancer in, Apr., 211
Blastoma: pulmonary, May, 285
Bleeding (*see* Hemorrhage)
Blood
abnormalities in inflammatory bowel disease, Oct., 628
flow, hepatic artery, effect of somatostatin and octreotide on, Dec., 763
gases, arterial, in asthma, Jan., 14; Mar., 166
pressure measurement, systemic arterial, with Swan-Ganz catheter, Aug., 525–529
direct vs. indirect measurements, Aug., 525–527
technique of arterial cannulation for, Aug., 527, 529
transfusions in radical prostatectomy, Apr., 234
Bloodstream: theophylline measurement in, Jan., 30
Bone
complications of inflammatory bowel disease, Nov., 702
scan in prostate cancer, Apr., 232
Bot: horse, causing solitary pulmonary nodules, May, 287
Bowel
(*See also* Intestine)
abnormalities in inflammatory bowel disease, Oct., 628
disease, inflammatory (*see* Inflammatory bowel disease)
short bowel syndrome, octreotide in, Dec., 790
small
efflux, somatostatin and octreotide in, Dec., 788–790
transplantation, in inflammatory bowel disease, Nov., 727
Brachytherapy: ^{125}I, in prostate cancer, Apr., 248–249
Bradycardia: in tetanus, Sept., 574
Brain stem tuberculoma: causing unilateral trismus, Sept., 583
Breast cancer: somatostatin and octreotide in, Dec., 785, 786
Breaths, mechanical, generation of
(*See also* Tidal volume generation)
methods, June, 339–340
Brethine: in asthma, Jan., 16
Bricanyl: in asthma, Jan., 16
Brodie, Sir Benjamin, Sept., 561
Bronchial
asthma (*see* Asthma)
hyperreactivity
angiotensin converting enzyme inhibitors and, Mar., 153
relation to acute allergic reaction and late asthmatic response, Mar., 158
hyperresponsiveness in asthma, Mar., 159–160
provocation testing in asthma, Mar., 170–171
occupational, Jan., 25
Bronchiolitis
in hypersensitivity pneumonitis, July, 424

obliterans-organizing pneumonia (*see* Pneumonia, bronchiolitis obliterans-organizing)
Bronchiolo-alveolar carcinomas, May, 283–284
Bronchitis: asthmatic, Mar., 153
Bronchoalveolar lavage
in Churg-Strauss syndrome, Feb., 110
in farmer's lung, July, 440–442
in hypersensitivity pneumonitis, July, 435–436
in interstitial lung disease, Feb., 124–126
in pulmonary alveolar proteinosis, Feb., 117
Bronchodilators: in asthma, Jan., 31; Mar., 172–177
Bronchogenic
carcinoma, May, 283–284
cyst, May, 289
Bronchopulmonary aspergillosis: allergic, Mar., 153, 155
Bronchoscopic biopsy: of solitary pulmonary nodules, May, 300–301
Bronchoscopy: fiberoptic, in interstitial lung disease, Feb., 124
Bronchospastic response: to inhalation of house dust mite extract, Mar., 156
Brucelloma: causing solitary pulmonary nodules, May, 287
Budesonide: in inflammatory bowel disease, Nov., 720
Byssinosis, July, 447

C

Cadmium exposure: and prostate cancer, Apr., 211
Calcification in solitary pulmonary nodules
imaging techniques, May, 298–299
patterns of, May, 286
Calcium channel blockers: in asthma, Jan., 43
Campylobacter jejuni, Nov., 709
Cancer
breast, somatostatin and octreotide in, Dec., 785, 786
colorectal
differentiated from inflammatory bowel disease, Nov., 710
in inflammatory bowel disease, Nov., 696, 701
lung (*see* Carcinoma, lung)
pancreas, somatostatin and octreotide in, Dec., 785–786
prostate, Apr., 209–268
adrenalectomy in, Apr., 252
age and, Apr., 209
androgen ablation in, total, Apr., 254
androgen deprivation in, methods of, Apr., 251–253
androgens in, circulation, removal of primary source of, Apr., 252
bone scan in, Apr., 232
chemotherapy in, Apr., 255–256
clinical observation in, Apr., 232–233
clinical presentation, Apr., 216–218
environmental factors in, Apr., 211–212
epidemiology, Apr., 209–212
estrogen therapy in, Apr., 252
evaluation of primary tumor, Apr., 224–229
flutamide in, Apr., 253
genetic influences on, Apr., 210–211
grading, Apr., 215–216
grading, Gleason system, Apr., 215
hormone dependence of, Apr., 250
hormone effects on, Apr., 210
hormone therapy in, Apr., 250–255
hormone therapy in, timing of, Apr., 254–255
hydrocortisone in, Apr., 253
hypophysectomy in, Apr., 252

Cancer *(cont.)*
infectious agents in, Apr., 212
ketoconazole in, Apr., 253
LHRH agonists in, Apr., 252–253
lymph node evaluation in (*see* Lymph nodes, pelvic, in prostate cancer)
metastases (*see* Metastases, from prostate cancer)
natural history, Apr., 216
octreotide in, Dec., 785
orchiectomy in, Apr., 252
pathological considerations in, Apr., 213–216
prostate anatomy and, Apr., 213–214
prostate hypertrophy and, benign, Apr., 212
prostatectomy in, radical (*see* Prostatectomy, radical, for prostate cancer)
race and, Apr., 211
radiotherapy in (*see* Radiotherapy in prostate cancer)
rectal examination in (*see* Rectal, examination, digital, in prostate cancer)
screening, Apr., 218–221
somatostatin in, Dec., 785
stage A, Apr., 222–223
stage A_1, untreated, mortality of, Apr., 233
stage B, Apr., 223
stage C, Apr., 223
stage D, Apr., 223
staging, classification, Apr., 222–223
staging, clinical, Apr., 224–232
staging, CT in, Apr., 225
staging, digital rectal examination in, Apr., 224
staging, DNA ploidy analysis in, Apr., 228–229
staging, Gleason score in, Apr., 228
staging, MRI in, Apr., 226
staging, prostate specific antigen in, Apr., 226–227
staging, transurethral resection in, Apr., 227–228
staging, ultrasound in, transrectal, Apr., 224–225
treatment, Apr., 232–255
ultrasound in, transrectal, for detection, Apr., 218
ultrasound in, transrectal, for detection, comparison to digital rectal examination, Apr., 219
surveillance in inflammatory bowel disease, Nov., 728–729
therapy, somatostatin and octreotide as, Dec., 784–788
Cannulation for Swan-Ganz catheterization
arterial, Aug., 527, 529
jugular vein, internal, Aug., 516–517
Capillary wedge pressure, pulmonary, with Swan-Ganz catheter, Aug., 521–522
respiration and, Aug., 523–524
Carbamazepine: causing pneumonitis, July, 459
Carcinoids: pulmonary, May, 284–285
Carcinoma
adenocarcinoma in inflammatory bowel disease, Nov., 701
bronchiolo-alveolar, May, 283–284
bronchogenic, May, 283–284
lung
non-small cell, surgery for, May, 303–304
small cell, surgery for, May, 304
tetanospasmin in study of, Sept., 575
prostate (*see* Cancer, prostate)
Carcinosarcoma: pulmonary, May, 285
Cardiac (*see* Heart)
Cardiomyopathy
restrictive, Swan-Ganz catheterization in, Aug., 539, 540
in tetanus, Sept., 574
Care: respiratory, physician's order for, June, 338
Cat(s): and asthma, Jan., 22–23

Catecholamines
in asthma, Mar., 173
elevations in tetanus, Sept., 573–574
Catheter
pulmonary artery, Aug., 485–508
(*see also* Catheter, Swan-Ganz *below*)
in acutely and seriously ill patient, Aug., 497–498
applications, broadening, Aug., 494–496
applications, human, Aug., 492–493
in clinical practice, routine, Aug., 496–499
clinical trials, Aug., 502–504
complications, Aug., 501–502
conclusion, Aug., 506
development (*see below*)
errors in monitoring, Aug., 499–501
prophylactic placement, Aug., 498–499
proprietary issues, Aug., 493–494
in standard setting, Aug., 504–505
pulmonary artery, development, Aug., 485–508
Cedars-Sinai, Los Angeles years, Aug., 489–490
Edwards Laboratory experience, Aug., 490–491
Ganz and, William, Aug., 491–494
historical background, Aug., 487
Mayo years, Aug., 488–489
Swan-Ganz, Aug., 509–543
(*See also* Catheter, pulmonary artery *above*)
applications, diagnostic, Aug., 532–541
applications, prognostic, Aug., 541, 543
applications, therapeutic, Aug., 541, 542–543
arterial cannulation technique, Aug., 527–529
blood pressure measurement with (*see* Blood, pressure measurement, systemic arterial)
cardiac output measurement with, Aug., 524–525
in cardiac tamponade, acute, Aug., 537–538, 539
in cardiomyopathy, restrictive, Aug., 539–540
complications, avoiding, Aug., 529–531
contraindications, Aug., 543
equipment used with (*see* Equipment for Swan-Ganz catheterization)
facilities and equipment, Aug., 513–514
insertion, Aug., 517–519
insertion, indications for, Aug., 531–532
insertion sites, Aug., 514–515
insertion technique, Aug., 513
jugular vein cannulation and, internal, Aug., 516–517
location and left atrial pressure, Aug., 522–523
in mitral regurgitation, acute, Aug., 533, 535
obtaining best measurements, Aug., 521–529
in pericarditis, constrictive, Aug., 539, 540
practical pointers, Aug., 519–521
preparation for insertion, Aug., 517–519
pulmonary capillary wedge pressure with, Aug., 521–522
pulmonary capillary wedge pressure with, and respiration, Aug., 523–524
in pulmonary edema, noncardiac, Aug., 537
in pulmonary embolism, acute massive, Aug., 537, 538
in pulmonary hypertension, chronic precapillary, Aug., 537
results, tips on interpreting, Aug., 521

Catheter *(cont.)*
in septic shock, Aug., 537
signal calibration, Aug., 512–513
in tricuspid regurgitation, Aug., 539, 541
in ventricular dysfunction, acute ischemic right, Aug., 532–533
in ventricular septal rupture, acute, Aug., 533, 536
Catheterization: cardiac, development of, Aug., 487–488
Cell(s)
"hand mirror," in hypersensitivity pneumonitis, July, 425
mast, degranulation in inflammatory bowel disease, Oct., 644
-mediated immunity in hypersensitivity pneumonitis, Feb., 85
plasma (*see* Plasma cell)
Central motor control effects: of tetanus, Sept., 569–573
Central nervous system inflammatory disease: somatostatin levels in, Dec., 796
Cephalic tetanus, Sept., 579, 580
Cetirizine: in asthma, Jan., 37
Cheese
washer's disease, July, 451
worker's disease, July, 450–451
Cheilitis: and Crohn's disease, Nov., 704–705
Chemicals: associated with diffuse pulmonary infiltrates, Feb., 121
Chemotherapy: in prostate cancer, Apr., 255–256
Chest x-rays (*see* Radiography, chest)
Children
asthma in (*see* Asthma)
glomerulonephritis in, immune complex, associated with Crohn's disease, Nov., 704
inflammatory bowel disease in, Nov., 694–695
newborn, tetanus in, Sept., 579–581
tetanus toxoid immunization in, Sept., 592
Chlorpheniramine: in asthma, Jan., 37
Cholangitis: sclerosing, in inflammatory bowel disease, Nov., 703
Cholecystokinin: effects of somatostatin and octreotide on, Dec., 772
Chondroma: of lung, May, 289
Chondrosarcoma: somatostatin and octreotide in, Dec., 785, 786
Chorea: Huntington's, somatostatin levels in, Dec., 796
Churg-Strauss syndrome, Feb., 108–110
clinical features, Feb., 109
diagnosis, Feb., 110
pathogenesis, Feb., 108–109
pathology, Feb., 108–109
therapy, Feb., 110
Cigarette smoking (*see* Smoking)
Cimetidine: vs. somatostatin and octreotide in peptic ulcer disease, Dec., 769
Circulation androgens: removal of primary source, in prostate cancer, Apr., 252
Cirrhosis: somatostatin and octreotide in, Dec., 762–765
Clear cell tumors: of lung, benign, May, 289
Clinical observation: in prostate cancer, Apr., 232–233
Clofazimine: in inflammatory bowel disease, Nov., 704
Clonidine: in tetanus, Sept., 590
Clostridium tetani
culture, gram stain of, Sept., 565
mature, schematic diagram of, Sept., 565
Clubbing: in pigeon breeder's lung, July, 443
CNS inflammatory disease: somatostatin levels in, Dec., 796
Coccidioidomas causing solitary pulmonary nodules, May, 285
cultures in, May, 287
Cockroach antigen: as cause of asthma, Jan., 22
Coffee worker's lung, July, 454

Colchicine: in progressive systemic sclerosis, Feb., 99
Cold air challenge: in asthma, Mar., 171
Colitis
antibiotic-associated, Nov., 709–710
collagenous, Nov., 705
Crohn's (*see* Crohn's disease)
Escherichia coli 0157.H7 hemorrhagic, Nov., 708–709
lymphocytic (microscopic), Nov., 705
radiation, Nov., 710–711
ulcerative (*see* Ulcerative colitis)
Collagen vascular disease-associated interstitial lung disease, Feb., 94
Collagenous colitis, Nov., 705
Colon
cancer (*see* Cancer, colorectal)
Crohn's disease, pathology, Nov., 692
Colorectal cancer (*see* Cancer, colorectal)
Complement
in inflammatory bowel disease, Oct., 639
pathway activation, alternate, in hypersensitivity pneumonitis, July, 428
Computed tomography (*see* Tomography, computed)
Connective tissue disease, mixed (*see* Mixed connective tissue disease)
Continuous positive airway pressure (*see* CPAP)
Corticosteroids
(*See also* Steroids)
in asthma, Jan., 17–18; Mar., 178–179
acute, Mar., 184–185
aerosol, Jan., 35–36
oral, Jan., 38–41
oral, dosage, Jan., 40–41
oral, side effects, Jan., 39
oral, side effects, adverse, Jan., 41
prophylactic, Mar., 182
in inflammatory bowel disease, Nov., 718–720
in lupus erythematosus, systemic, Feb., 102
in pneumonia, chronic eosinophilic, Feb., 94
in pulmonary fibrosis, idiopathic, Feb., 80
in tetanus, Sept., 587
Cost: of leuprolide and goserelin in prostate cancer, Apr., 253
CPAP, June, 355–356
controls on ventilators, June, 368–369
generation
with exhalation diaphragm, spring-loaded, June, 359
with exhalation diaphragm, weighted, June, 360
with exhaled gas directed against opposing gas flow, June, 360
with tube under water, June, 359
system, typical face mask, June, 356
Creola bodies: in asthma, Mar., 168
Crohn's disease, Nov., 685–694
(*See also* Inflammatory bowel disease)
alimentation in, continuous enteral elemental, Nov., 723
of colon, pathology, Nov., 692
discussion of, Oct., 649–651
distinctions and comparisons between ulcerative colitis and, Nov., 693
endoscopy in, Nov., 688
of ileum, Nov., 691
pathology, Nov., 689–692
radiology in, Nov., 688–689
sites, Nov., 692–694
Cromoglycate: in inflammatory bowel disease, Nov., 704
Cromolyn sodium in asthma, Jan., 34; Mar., 177–178
prophylactic, Mar., 182
Cryptococcosis: presenting as solitary pulmonary nodule, May, 286

CT (*see* Tomography, computed)
Culture
  of *Clostridium tetani*, gram stain of, Sept., 565
  sputum, in solitary pulmonary nodules, May, 300
Cyclophosphamide
  in Churg-Strauss syndrome, Feb., 110
  in Goodpasture's syndrome, Feb., 114–115
  in granulomatosis
    lymphomatoid, Feb., 112
    Wegener's, Feb., 107
  in mixed connective tissue disease, Feb., 101
  in polymyositis/dermatomyositis interstitial lung disease, Feb., 100
  in pulmonary fibrosis, idiopathic, Feb., 81
Cyclosporine: in inflammatory bowel disease, Nov., 720, 721
Cyst: bronchogenic, May, 289
Cytokines: in inflammatory bowel disease, Oct., 630–631
Cytology: sputum, in solitary pulmonary nodules, May, 299–300
Cytomegalovirus
  in inflammatory bowel disease, Oct., 636
  in prostate cancer, Apr., 212
  pulmonary nodules due to, solitary, May, 287

D

Dantrolene: in tetanus, Sept., 589
Death (*see* Mortality)
Decision
  analysis
    discussion of term, May, 305
    studies of solitary pulmonary nodules, May, 305–307
  approaches to solitary pulmonary nodules, quantitative, May, 304–307
Demography: in inflammatory bowel disease, Oct., 625–627
Deoxyribonucleic acid ploidy analysis: in prostate cancer staging, Apr., 228–229
Dermatologic problems: in Crohn's disease, Nov., 704
Dermatomyositis (*see* Polymyositis/dermatomyositis)
DES: in prostate cancer, Apr., 252
Detergent worker's lung, July, 446
Developmental retardation: after neonatal tetanus, Sept., 581
DF3 antigen: in inflammatory bowel disease, Oct., 629
Diaphragmatic paralysis: in tetanus, Sept., 578
Diarrheas: infectious, differentiated from inflammatory bowel disease, Nov., 706, 708
Diazepam: in tetanus, Sept., 589
Dibenamine: in asthma, Jan., 43
Diet
  asthma and, Mar., 180
  in inflammatory bowel disease, Nov., 712–714
  in pancreatitis, acute, Dec., 777
  prostate cancer and, Apr., 211–212
Diethylstilbestrol: in prostate cancer, Apr., 252
Dihydrotestosterone levels: in prostate cancer, Apr., 210
Dirofilariasis: presenting as solitary pulmonary nodule, May, 287
Disodium cromoglycate: in inflammatory bowel disease, Nov., 704
Diverticulitis: with Crohn's disease, Nov., 710
DNA ploidy analysis: in prostate cancer staging, Apr., 228–229
Drug(s)
  antibacterial, in inflammatory bowel disease, Nov., 717–720
  anticholinergic (*see* Anticholinergic drugs)
  antidiarrheal, in inflammatory bowel disease, Nov., 714–715
  anti-inflammatory (*see* Anti-inflammatory agents)

antispasmodic, in inflammatory bowel disease, Nov., 714–715
antispasticity, in tetanus, Sept., 589–590
immunosuppressive, in inflammatory bowel disease, Nov., 720–721
-induced granulomatous pneumonitis, pulmonary, July, 459–460
potential new, in inflammatory bowel disease, Nov., 730
pulmonary injury due to, diffuse, Feb., 122
therapy in asthma (*see* Asthma, drug therapy in)
Dumping syndrome: somatostatin and octreotide in, Dec., 778–784
Duodenum: Crohn's disease of, Nov., 693–694
Dust
inorganic, associated with diffuse pulmonary infiltrates, Feb., 120
mite extract, house, bronchospastic response to inhalation of, Mar., 156
wood dust diseases, July, 452
Dysphagia: in cephalic tetanus, Sept., 579

E

Edema: noncardiac pulmonary, Swan-Ganz catheterization in, Aug., 537
Efflux: small bowel, somatostatin and octreotide in, Dec., 788–790
Elderly
asthma in, Mar., 188
inflammatory bowel disease in, Nov., 694–695
mortality of surgery for solitary pulmonary nodules in, May, 303
tetanus therapy in, Sept., 585
Electromyography: in tetanus diagnosis, Sept., 581
Electron microscopy
in histiocytosis X, Feb., 89
in pneumonitis, hypersensitivity, July, 425
Electronic monitoring equipment for Swan-Ganz catheterization (*see* Equipment for Swan-Ganz catheterization, electronic monitoring)
Elemental
alimentation in Crohn's disease, Nov., 723
diet in inflammatory bowel disease, Nov., 713
ELISA: in asthma, Mar., 171
Embolism: acute massive pulmonary, Swan-Ganz catheterization in, Aug., 537, 538
Encephalography: in tetanus, Sept., 578
Endocrinology: prostate, Apr., 250–251
Endometrioma: pulmonary, May, 289
Endoscopy
in Crohn's disease, Nov., 688
in ulcerative colitis, Nov., 684
Enema: steroid, in inflammatory bowel disease, Nov., 719
Enkephalin release: inhibition by tetanospasmin, Sept., 573
Enterocolitis: collagenous, Nov., 705
Environmental factors
in inflammatory bowel disease, Oct., 625–627
in prostate cancer, Apr., 211–212
Enzyme
inhibitors, angiotensin converting, and bronchial hyperreactivity, Mar., 153
-linked immunosorbent assay in asthma, Mar., 171
secretion in pancreas after somatostatin, Dec., 772
Eosinophilic pneumonia (*see* Pneumonia, eosinophilic)
Epidermal growth factor: in peptic ulcer healing, Dec., 770
Epidermolysis bullosa acquisita: in Crohn's disease, Nov., 704

Epidural anesthesia: in tetanus, Sept., 590
Epilepsy: tetanospasmin in study of, Sept., 575
Epinephrine: in asthma, Jan., 16
Epithelium
  intestinal, in inflammatory bowel disease, Oct., 629
  intraepithelial neoplasia, prostatic, Apr., 214–215
Equipment for Swan-Ganz catheterization, Aug., 509, 513–514
  checklist of, Aug., 514
  choosing and using, Aug., 509
  electronic monitoring, Aug., 511
    catheter whip artifact, Aug., 511
    damping, Aug., 511
    frequency response, Aug., 511
    natural frequency, Aug., 511
Erythrocyte antigen: P1, in hypersensitivity pneumonitis, July, 421
Escherichia coli 0157.H7 hemorrhagic colitis, Nov., 708–709
Esophagus
  Crohn's disease of, Nov., 693
  gastroesophageal reflux and asthma, Jan., 25
Estrogen therapy: in prostate cancer, Apr., 252
Ethambutal: in inflammatory bowel disease, Nov., 718
Ethylenediamine: in theophylline preparations, Jan., 28
Exercise challenge: in asthma, Mar., 171
Expectorants: in asthma, Jan., 42
Expiratory curve: forced, interpretation methods in asthma, Mar., 165
Expiratory pressure, positive end (*see* PEEP)
Extracorporeal perfusion: for theophylline toxicity, Jan., 30

F

Facial nerve weakness: in cephalic tetanus, Sept., 579
Farmer's lung (*see* Lung, farmer's)
Fat intake: and prostate cancer, Apr., 211–212
Feather-picker's disease, July, 456–457
Fecal abnormalities: in inflammatory bowel disease, Oct., 628
FEV_1 decrease: in asthma, Mar., 170
Fiber intake: and inflammatory bowel disease, Nov., 712
Fiberoptic bronchoscopy: in interstitial lung disease, Feb., 124
Fibrosis, idiopathic pulmonary (*see* Pulmonary, fibrosis, idiopathic)
Fish oils: in inflammatory bowel disease, Nov., 712–713
Fistula: pancreatic, somatostatin and octreotide in, Dec., 770–778
Fluids: intravenous, in asthma, Jan., 14–15
Flunisolide: in asthma, Jan., 35; Mar., 179
Fluoroscopy: in solitary pulmonary nodules, May, 294
Flutamide: in prostate cancer, Apr., 253
Forced expiratory curve: interpretation methods in asthma, Mar., 165
Foreign body particles: in hypersensitivity pneumonitis, July, 424
Formoterol: in asthma, Jan., 34
Fuel-chip induced hypersensitivity pneumonitis, July, 449
Fungi: and asthma, Jan., 23
Furrier's lung, July, 455

G

Gallbladder abnormalities: in inflammatory bowel disease, Nov., 702–703
Gamma globulin: IV, in asthma, Jan., 47–48
Gangliosides: role in neurotransmission, tetanospasmin in study of, Sept., 575
Ganz, William, Aug., 491–494

Gas(es)
arterial blood, in asthma, Jan., 14; Mar., 166
flow
diagram for Siemens Servo ventilator, June, 382
during ventilation, high-frequency (*see* Ventilation, high-frequency, gas flow during)
through ventilator, Bennett MA-1, June, 371
through ventilator, high-frequency jet, June, 397
Gastric (*see* Stomach)
Gastrinoma: somatostatin and octreotide in, Dec., 785
Gastroesophageal reflux: and asthma, Jan., 25
Gastrointestinal
(*See also* Intestine; Stomach)
tract
lesions as source of tetanus, Sept., 582
upper, Crohn's disease of, Nov., 692–693
Generator
constant-flow, June, 345–347
Bennett MA-1 ventilator as, June, 373
pressure, flow, and volume wave forms for, June, 346
constant-pressure, June, 349–350
pressure, flow, and volume curves for, June, 350
nonconstant-flow, June, 347–349
flow wave pattern of, June, 348
mechanics of, June, 349
piston, mechanics of, June, 347
nonconstant-pressure, June, 350–351
Genetic
factors in pulmonary alveolar proteinosis, Feb., 116
influences
in inflammatory bowel disease, Oct., 645–649
in prostate cancer, Apr., 210–211
Gleason grading system: in prostate cancer, Apr., 215
Gleason score: in prostate cancer staging, Apr., 228
Glomerulonephritis: immune complex, in Crohn's disease, in children, Nov., 704
Glucocorticoids (*see* Corticosteroids)
Glycerol: iodinated, in asthma, Jan., 42–43
Glycoproteins: in inflammatory bowel disease, Oct., 629
Glycopyrrolate: in asthma, Jan., 37
Gold: in asthma, Jan., 47; Mar., 179
Goodpasture's syndrome, Feb., 112–115
clinical features, Feb., 114
diagnosis, Feb., 114
pathogenesis, Feb., 113–114
pathology, Feb., 113–114
therapy, Feb., 114–115
Goserelin acetate: in prostate cancer, Apr., 252–253
Globulin
gamma, IV, in asthma, Jan., 47–48
immune (*see* Immunoglobulin)
Grain weevil disease, July, 456
Gram stain: of culture of *Clostridium tetani*, Sept., 565
Granuloma
formation in hypersensitivity pneumonitis, July, 424
mechanism of, July, 429
infectious, presenting as solitary pulmonary nodules, May, 285–286
noninfectious, presenting as solitary pulmonary nodules, May, 287
Penicillium, presenting as solitary pulmonary nodule, May, 286
pulmonary
common, histologic features, July, 426
hyalinizing, presenting as solitary pulmonary nodule, May, 287
plasma cell, May, 287

Granulomatosis
lymphomatoid, interstitial lung disease in, Feb., 110–112
clinical features, Feb., 111–112
diagnosis, Feb., 112
pathogenesis, Feb., 111
pathology, Feb., 111
therapy, Feb., 112
Wegener's, interstitial lung disease in, Feb., 103–108
clinical features, Feb., 104–107
diagnosis, Feb., 107
pathogenesis, Feb., 103–104
pathology, Feb., 103–104
radiography in, Feb., 105
therapy, Feb., 107–108
Wegener's, solitary pulmonary nodules of, May, 287
Granulomatous
diseases, pulmonary, chest roentgenographic features of, July, 441
pneumonitis (*see* Pneumonitis, granulomatous)
Growth
complications of inflammatory bowel disease, Nov., 701–702
factor, epidermal, in peptic ulcer healing, Dec., 770
hormone-producing pituitary adenoma, somatostatin and octreotide in, Dec., 785
Guaifenesin: in asthma, Jan., 43
Gut
-associated immune events in inflammatory bowel disease, Oct., 641–642
irrigation, whole, in inflammatory bowel disease, Nov., 724

H

Hamartoma: pulmonary, May, 287–288
"Hand mirror" cells: in hypersensitivity pneumonitis, July, 425
Hard metal pneumoconiosis, July, 458–459
Heart
catheterization, development of, Aug., 487–488
monitoring in asthma, Jan., 15
output measurement with Swan-Ganz catheter, Aug., 524–525
pacemaker in tetanus, Sept., 590
rate during asthma attack, Mar., 164
tamponade, acute, Swan-Ganz catheterization in, Aug., 537–538, 539
Hemangioendothelioma: pulmonary, May, 285
Hemodynamic
monitoring (*see* Catheter, pulmonary artery; Catheter, Swan-Ganz)
pressures, normal, Aug., 518
Hemorrhage
alveolar hemorrhage syndrome, diffuse, diseases causing, Feb., 113
variceal, somatostatin and octreotide in, Dec., 762–765
Hemorrhagic colitis: *Escherichia coli* 0157.H7, Nov., 708–709
Hepatic
(*See also* Liver)
artery blood flow, effect of somatostatin and octreotide on, Dec., 763
Hepatobiliary abnormalities: in inflammatory bowel disease, Nov., 702–703
High-frequency ventilation (*see* Ventilation, high-frequency)
Histamine
challenge in asthma, Mar., 170
H_1 receptor antagonists in asthma, Jan., 37
Histiocytosis X, primary pulmonary, Feb., 88–92
clinical features, Feb., 90
diagnosis, Feb., 90
histology, Feb., 89
pathogenesis, Feb., 88–90
pathology, Feb., 88–90
roentgenogram in, Feb., 91
therapy, Feb., 91–92

Histoplasmomas: causing solitary pulmonary nodules, May, 285
History
in lung disease, interstitial, Feb., 118–119
of pneumonitis, hypersensitivity, July, 419
of pulmonary artery catheter development, Aug., 487
of pulmonary nodules, solitary, May, 279–280
of tetanus, Sept., 559–561
of ventilation
high-frequency, June, 395–396
mechanical, June, 331–333
HIV infection
tetanus toxoid immunization and, Sept., 593
ulcerative colitis in, Oct., 639
HLA
antigen distributions in inflammatory bowel disease, Oct., 647
associations in hypersensitivity pneumonitis, July, 420–421
Home parenteral nutrition: in inflammatory bowel disease, Nov., 714
Hormone
adrenal androgen hormone synthesis, hypothalamic pituitary regulation of, Apr., 251
antidiuretic, inappropriate secretion, in tetanus, Sept., 574
dependence of prostate cancer, Apr., 250
effects on prostate cancer, Apr., 210
growth hormone-producing pituitary adenoma, somatostatin and octreotide in, Dec., 785
influences in asthma, Jan., 25–26
luteinizing hormone-releasing hormone agonists in prostate cancer, Apr., 252–253
therapy in prostate cancer, Apr., 250–255
timing of, Apr., 254–255
Horse bot: causing solitary pulmonary nodules, May, 287
Hospitalization
for asthma, Jan., 19
for inflammatory bowel disease, Nov., 711
House dust mite extract: bronchospastic response to inhalation of, Mar., 156
Human immunodeficiency virus infection (*see* HIV infection)
Humidifier lung, July, 447–448
Humoral immunity: in inflammatory bowel disease, Oct., 638–639
Huntington's chorea: somatostatin levels in, Dec., 796
Hyalinizing pulmonary granuloma: presenting as solitary pulmonary nodule, May, 287
Hydrocortisone
in asthma, Jan., 18
in prostate cancer, Apr., 253
Hydronephrosis: in Crohn's disease, Nov., 704
Hyperalimentation: in inflammatory bowel disease, Nov., 712–714
Hyperbaric oxygen: in Crohn's disease, Nov., 724
Hypersensitivity
alginate pulmonary, July, 457–458
delayed, after tetanus toxoid, Sept., 594
pneumonitis (*see* Pneumonitis, hypersensitivity)
Hypertension, pulmonary (*see* Pulmonary, hypertension)
Hyperthyroidism: and asthma, Jan., 25–26
Hypertrophy: benign prostatic, and prostate cancer, Apr., 212
Hypokalemia: after beta agonists in asthma, Jan., 33
Hypophysectomy: in prostate cancer, Apr., 252
Hypotension
autonomic, somatostatin and octreotide in, Dec., 794
in tetanus, Sept., 574

Hypothalamic pituitary regulation: of testosterone and adrenal androgen hormone synthesis, Apr., 251
Hypoxemia: after beta agonists in asthma, Jan., 33

I

Ileitis: *Yersinia*, Nov., 709
Ileoanal procedure: in inflammatory bowel disease, Nov., 726
Ileorectal anastomosis: in inflammatory bowel disease, Nov., 726
Ileum: Crohn's disease of, Nov., 691
Imaging
(*See also* Scanning)
magnetic resonance (*see* Magnetic resonance imaging)
of solitary pulmonary nodules, May, 294–299
calcification in, May, 298–299
nodule/lung interface in, May, 296–297
perinodular abnormalities, May, 298
selection of technique, May, 294–295
shape and size in, May, 295–296
Immune
complex
glomerulonephritis in Crohn's disease, in children, Nov., 704
mechanisms in hypersensitivity pneumonitis, July, 425, 427
events, gut-associated, in inflammatory bowel disease, Oct., 641–642
globulin (*see* Immunoglobulin)
status, antitetanus, determination of, Sept., 584
Immunity
cell-mediated, in hypersensitivity pneumonitis, Feb., 85
humoral, in inflammatory bowel disease, Oct., 638–639
Immunization, tetanus toxoid (*see* Tetanus, toxoid immunization)
Immunodeficiency virus infection, human (*see* HIV infection)
Immunoglobulin
human tetanus, Sept., 585, 587
levels in hypersensitivity pneumonitis, July, 436
Immunologic
comment in inflammatory bowel disease, Oct., 643–644
considerations in inflammatory bowel disease, Oct., 637–649
reactivity of host in hypersensitivity pneumonitis, July, 420
Immunoregulatory activity: in inflammatory bowel disease, Oct., 643
Immunosuppressive
drugs in inflammatory bowel disease, Nov., 720–721
factor in inflammatory bowel disease, Oct., 644
Immunotherapy
in asthma, Jan., 48–49; Mar., 180–181
in Goodpasture's syndrome, Feb., 114
in tetanus, Sept., 585–587
Impotency
after prostatectomy, radical, Apr., 234
after radiotherapy for prostate cancer, external beam, Apr., 245
IMV (*see* Ventilation, intermittent mandatory)
Incontinence: urinary, after radical prostatectomy, Apr., 234, 238
Indium-11 scanning: in Crohn's disease, Nov., 689
Indoram: in asthma, Jan., 44
Infarct: pulmonary, May, 289
Infectious
agents in prostate cancer, Apr., 212
diarrheas differentiated from inflammatory bowel disease, Nov., 706, 708
granulomas presenting as solitary pulmonary nodules, May, 285–286

Infertility: male, after sulfasalazine, Nov., 716
Inflammatory bowel disease, Oct., 625–666; Nov., 679–746
(*See also* Crohn's disease; Ulcerative colitis)
animal, Oct., 632–634
antidepressants in, Nov., 715–717
antigen-antibody complexes in, Oct., 639–640
antigens in, HLA, Oct., 647
autoimmunity in, Oct., 642–643
blood abnormalities in, Oct., 628
bowel abnormalities in, Oct., 628
cancer surveillance in, Nov., 728–729
in children, Nov., 694–695
clinical aspects, Nov., 679–682
colorectal cancer and, Nov., 696, 701
complement in, Oct., 639
complications, Nov., 696–705
involving bone, Nov., 702
involving growth, Nov., 701–702
overview, Nov., 705
treatment, Nov., 724–725
demography, Oct., 625–627
diet in, Nov., 712–714
differential diagnosis, Nov., 705–711
drugs in
antibacterial, Nov., 717–720
antidiarrheal, Nov., 714–715
antispasmodic, Nov., 714–715
immunosuppressive, Nov., 720–721
potential new, Nov., 730
in elderly, Nov., 694–695
environment and, Oct., 625–627
etiologic overview, Nov., 679–682
experimental, Oct., 632–634
fecal abnormalities in, Oct., 628
genetic influences in, Oct., 645–649
hepatobiliary abnormalities in, Nov., 702–703
hospitalization for, Nov., 711
hyperalimentation in, Nov., 712–714
immune events in, gut-associated, Oct., 641–642
immunity in, humoral, Oct., 638–639
immunologic comment in, Oct., 643–644
immunologic considerations in, Oct., 637–649
immunoregulatory activity in, Oct., 643
intestinal tissue abnormalities in, Oct., 627–632
laboratory findings in, Nov., 683
lymphocytes in, circulating, Oct., 640–641
microbiologic considerations in, Oct., 635–637
mimicry, Nov., 705, 706
nature, Oct., 625–666
nutritional deficiencies in, Nov., 701
pathogenesis, Oct., 625–666
proposed sequence of events in, Oct., 651–653
in pregnancy, Nov., 695–696
prognosis, Nov., 730–732
psychogenic contributions in, Oct., 634–635
sedatives in, Nov., 715–717
summary, Oct., 652–653
surgery in, Nov., 725–728
indications, Nov., 726
systemic defenses in, Oct., 644–649
treatment, Nov., 711–730
medical, Nov., 711–730
medical, general principles, Nov., 711
medical, in representative clinical situations, Nov., 721–724
medical, suggested initial approach, Nov., 722
subsequent, Nov., 728–729
summary, Nov., 729–730
supportive, Nov., 714–721
Inflammatory CNS disease: somatostatin levels in, Dec., 796
Inflammatory polyneuropathy: after tetanus toxoid, Sept., 594

Inhalation: of house dust mite extract, bronchospastic response to, Mar., 156
Inhalational exposure: and pulmonary alveolar proteinosis, Feb., 116
Inhaler, metered dose, in asthma, Jan., 16
  recommended procedures for optimum use, Mar., 174
Inheritance: and asthma, Mar., 155
Injury: tetanus immunization after, Sept., 593–594
Insulinoma: somatostatin and octreotide in, Dec., 785
Integrins: in inflammatory bowel disease, Oct., 629
Interstitial
  infiltration in hypersensitivity pneumonitis, July, 424
  lung disease (*see* Lung, disease, interstitial)
Intestine
  (*See also* Bowel; Gastrointestinal)
  epithelial barrier in inflammatory bowel disease, Oct., 629
  polypeptide, vasoactive, in dumping syndrome, Dec., 780–781
  small, Crohn's disease of, Nov., 691
  tissue abnormalities in inflammatory bowel disease, Oct., 627–632
  tuberculosis, Nov., 709
Intoxication: strychnine, differentiated from tetanus, Sept., 582–583
Intraalveolar
  buds in hypersensitivity pneumonitis, July, 424
  macrophages in hypersensitivity pneumonitis, July, 424
Intraepithelial neoplasia: prostatic, Apr., 214–215
Intrathecal human tetanus immune globulin, Sept., 585, 587
Intrathoracic splenosis, May, 289
Intravariceal pressure: effect of somatostatin and octreotide on, Dec., 764
Iodide (*see* Potassium, iodide)
Iodinated glycerol: in asthma, Jan., 42–43
Iodine-125 brachytherapy: in prostate cancer, Apr., 248–249
Ipecac: for theophylline toxicity, Jan., 30
Ipratropium in asthma, Mar., 177, 185
  chronic, Jan., 36–37
  severe, Jan., 17
Irradiation (*see* Radiation)
Irrigation: whole gut, in inflammatory bowel disease, Nov., 724
Ischemic ventricular dysfunction: acute right, Swan-Ganz catheterization in, Aug., 532–533

J

Jejunoileitis, Nov., 694
Jet
  ventilation, high-frequency, June, 397
  ventilator, high-frequency, gas flow through, June, 397
Jugular vein: internal, cannulation method for Swan-Ganz catheterization, Aug., 516–517

K

Ketoconazole: in prostate cancer, Apr., 253
Ketotifen: in asthma, Jan., 37–38

L

Labetalol: in tetanus, Sept., 590
Laboratory
  evaluation in interstitial lung disease, Feb., 122–123
  findings in inflammatory bowel disease, Nov., 683
  tests in asthma, Mar., 167–168
Lavage, bronchoalveolar (*see* Bronchoalveolar lavage)
Leukemia: acute, in inflammatory bowel disease, Nov., 704
Leuprolide acetate: in prostate cancer, Apr., 252–253

LHRH agonists: in prostate cancer, Apr., 252–253
Liver
abscess in inflammatory bowel disease, Nov., 704
transplantation in inflammatory bowel disease, Nov., 725
Loratadine: in asthma, Jan., 37
Lorazepam: in tetanus, Sept., 589
Lung
(*See also* Pulmonary)
abscess, *Pseudomonas aeruginosa*, May, 287
biopsy (*see* Biopsy, lung)
bird fancier's, July, 442–444
blastoma, May, 285
cancer (*see* Carcinoma, lung)
carcinoma (*see* Carcinoma, lung)
carcinosarcoma, May, 285
chondroma, May, 289
coffee worker's, July, 454
detergent worker's, July, 446
diseases, granulomatous, chest roentgenographic features of, July, 441
disease, interstitial, Feb., 73–133
approach to, Feb., 117–126
biopsy in, extrathoracic, Feb., 126
biopsy in, open lung, Feb., 126
bronchoalveolar lavage in, Feb., 124–126
bronchoscopy in, fiberoptic, Feb., 124
in Churg-Strauss syndrome (*see* Churg-Strauss syndrome)
collagen vascular disease-associated, Feb., 94
CT in, Feb., 121
diagnosis, differential, Feb., 74
exposures and, specific, Feb., 119, 120–121, 122
in granulomatosis, lymphomatoid (*see* Granulomatosis, lymphomatoid)
in granulomatosis, Wegener's (*see* Granulomatosis, Wegener's, interstitial lung disease in)
history in, Feb., 118–119
laboratory evaluation in, Feb., 122–123
in lupus erythematosus (*see* Lupus erythematosus, systemic)
in mixed connective tissue disease (*see* Mixed connective tissue disease)
physical examination in, Feb., 119
in polymyositis/dermatomyositis (*see* Polymyositis/dermatomyositis)
pulmonary function tests in, Feb., 123–124
radiography in, Feb., 119, 123
rheumatoid (*see* Rheumatoid arthritis, lung disease in, interstitial)
in sclerosis, progressive systemic (*see* Sclerosis, progressive systemic)
symptoms in, Feb., 118–119
disease, obstructive, chronic
(*See also* Asthma)
drug therapy in, Jan., 11–58
diseases in upper lung fields, differential diagnosis, July, 434
endometrioma, May, 289
farmer's, July, 439–442
(*See also* Pneumonitis, hypersensitivity)
bronchoalveolar lavage in, July, 440–442
furrier's, July, 455
hamartoma, May, 287–288
hemangioendothelioma, May, 285
humidifier, July, 447–448
lymphoma, May, 285
maltworker's, July, 456
maple bark stripper's, July, 452–453
melanoma, May, 285
mushroom worker's, July, 449–450
New Guinea, July, 454
paprika splitter's, July, 456

Lung *(cont.)*
pigeon breeder's, July, 442–444
pituitary snuff taker's, July, 454–455
potato riddler's, July, 457
sarcoma, May, 285
sisal worker's, July, 453
smallpox handler's, July, 457
spätlese, July, 450
tumors
benign, May, 289
clear cell, benign, May, 289
vineyard sprayer's, July, 453
Lupron: in prostate cancer, Apr., 252–253
Lupus erythematosus, systemic, interstitial lung disease in, Feb., 101–102
diagnosis, Feb., 102
therapy, Feb., 102
Luteinizing hormone-releasing hormone agonists: in prostate cancer, Apr., 252–253
Lymph nodes, pelvic, in prostate cancer
CT of, Apr., 229
dissection of, staging, Apr., 229–230
evaluation of, Apr., 229
lymphangiography of, Apr., 229
MRI of, Apr., 229
Lymphangiography: of pelvic nodes in prostate cancer, Apr., 229
Lymphangioma: pulmonary, May, 289
Lymphocyte(s)
circulating, in inflammatory bowel disease, Oct., 640–641
increase in hypersensitivity pneumonitis, July, 435
T, apheresis in inflammatory bowel disease, Nov., 721
Lymphocytic colitis, Nov., 705
Lymphoma
in inflammatory bowel disease, Nov., 701
lung, May, 285
Lymphomatoid granulomatosis (*see* Granulomatosis, lymphomatoid)

M

Macrophages: intraalveolar, in hypersensitivity pneumonitis, July, 424
Magnesium
in asthma, Jan., 18
deficiency in inflammatory bowel disease, treatment, Nov., 714
Magnetic resonance imaging
of carcinoids, pulmonary, May, 285
of pelvic nodes in prostate cancer, Apr., 229
in prostate cancer staging, Apr., 226
of pulmonary arteriovenous aneurysms, May, 295
of pulmonary nodules, solitary, May, 295
Maltworker's lung, July, 456
Maple bark stripper's lung, July, 452–453
Margarine: and inflammatory bowel disease, Nov., 712
Mast cell degranulation: in inflammatory bowel disease, Oct., 644
Measles: atypical, causing solitary pulmonary nodules, May, 287
Melanoma: lung, May, 285
Menstruation: and asthma, Jan., 25
6-Mercaptopurine: in inflammatory bowel disease, Nov., 720–721
Mesalamine: in inflammatory bowel disease, Nov., 716–717
Mesalazine: in inflammatory bowel disease, Nov., 717
Metal: hard metal pneumoconiosis, July, 458–459
Metaprel: in asthma, Jan., 15
Metaproterenol: in asthma, Jan., 15
Metastases
from Crohn's disease, Nov., 704–705
from prostate cancer
distant, evaluation of, Apr., 230–232
vertebral, osteoblastic, Apr., 231
pulmonary nodules, solitary, May, 284

Metered dose inhaler in asthma, Jan., 16
recommended procedures for optimum use, Mar., 174
Methacholine challenge: in asthma, Mar., 170–171
Methotrexate
in asthma, Jan., 46; Mar., 179
pneumonitis due to, July, 459
Methylprednisolone: in asthma, Jan., 18; Mar., 178
Methylxanthine: in asthma, Jan., 16; Mar., 175–177
Metronidazole
in inflammatory bowel disease, Nov., 717–718
in tetanus, Sept., 588
Microbial causes: of inflammatory bowel disease, Oct., 636
Microbiologic considerations: in inflammatory bowel disease, Oct., 635–637
Microprocessor ventilator (*see* Bennett 7200 ventilator)
Microscopic colitis, Nov., 705
Microscopy, electron (*see* Electron microscopy)
Midazolam: in tetanus, Sept., 589
Mite extract: house dust, bronchospastic response to inhalation of, Mar., 156
Mitral regurgitation: acute, Swan-Ganz catheterization in, Aug., 533, 535
Mixed connective tissue disease, interstitial lung disease in, Feb., 100–101
diagnosis, Feb., 101
therapy, Feb., 101
Molds: and asthma, Jan., 23
Monitor(s): ventilator, June, 366–367
Monitoring
cardiac, in asthma, Jan., 15
equipment, electronic, for Swan-Ganz catheterization (*see* Equipment for Swan-Ganz catheterization, electronic monitoring)
hemodynamic (*see* Catheter, pulmonary artery; Catheter, Swan-Ganz)
Morbidity
of prostatectomy, radical (*see* Prostatectomy, radical, for prostate cancer, morbidity of)
of radiotherapy, external beam, in prostate cancer, Apr., 246
of tetanus, Sept., 563
Morphine: in tetanus, Sept., 590
Mortality
of asthma, Mar., 150, 190
age-specific, Mar., 151
in Crohn's disease, Nov., 731–732
of prostate cancer, untreated stage A_1, Apr., 233
of prostatectomy, radical (*see* Prostatectomy, radical, for prostate cancer, mortality of)
of radiotherapy, external beam, in prostate cancer, Apr., 246
of surgery for solitary pulmonary nodules, May, 303
of tetanus, Sept., 563
in ulcerative colitis, Nov., 731
Motilin
in dumping syndrome, Dec., 781
effects of somatostatin and octreotide on, Dec., 772
Motor control: central, tetanus effects on, Sept., 569–573
Mouth: Crohn's disease of, Nov., 692–693
MRI (*see* Magnetic resonance imaging)
Mucoid impaction, May, 289
Mucokinetic drugs: in asthma, Jan., 43
Mucolytics: in asthma, Jan., 42
Mucomyst: in asthma, Jan., 43
Mucormycosis: presenting as solitary pulmonary nodule, May, 286
Multiple sclerosis: somatostatin levels in, Dec., 796
Muscle fatigue: causing respiratory failure, June, 334–336

Mushroom worker's lung, July, 449–450
Mycobacterial infections: nontuberculous, presenting as solitary pulmonary nodule, May, 286
Myositis ossificans circumscripta: as complication of tetanus, Sept., 591

N

Narcotic(s)
addicts, severity of tetanus in, Sept., 576
in inflammatory bowel disease, Nov., 704
Nedocromil: in asthma, Jan., 38
Neonatal tetanus, Sept., 579–581
Neoplasia: prostatic intraepithelial, Apr., 214–215
Nephrolithiasis: in inflammatory bowel disease, Nov., 703
Nerve
facial, weakness in cephalic tetanus, Sept., 579
renal, sympathetic, tetanus effects on, Sept., 574
Nervous system
autonomic
dysfunction in tetanus, generalized, Sept., 578
dysfunction in tetanus, therapy, Sept., 590
tetanus effects on, Sept., 573–574
central, inflammatory disease, somatostatin levels in, Dec., 796
Neural mechanisms: in asthma, Mar., 160
Neuroblastoma: tetanospasmin in study of, Sept., 575
Neuroendocrine influences: in inflammatory bowel disease, Oct., 631–632
Neurologic disease: somatostatin in etiology of, Dec., 795
Neuromuscular junction
blockade in tetanus, Sept., 590
tetanus effects on, Sept., 574–575
Neuropathologic complications: peripheral, of tetanus toxoid, Sept., 594
Neuropathy: autonomic, somatostatin and octreotide in, Dec., 794
Neuropeptides: in asthma, Mar., 160
Neurotensin: in dumping syndrome, Dec., 781
Neurotransmission: tetanospasmin in study of role of gangliosides in, Sept., 575
Neutrophils: in inflammatory bowel disease, Oct., 630
New Guinea lung, July, 454
Nocturnal asthma (*see* Asthma, nocturnal)
Nodules (*see* Pulmonary, nodules)
Norepinephrine
elevations in tetanus, Sept., 573–574
release inhibited by tetanospasmin, Sept., 573
Nutrition
deficiencies in inflammatory bowel disease, Nov., 701
in tetanus, Sept., 591

O

Occupational
asthma, Mar., 153
causes, Mar., 154
risks and prostate cancer, Apr., 211
triggers of asthma, Jan., 24–25
Octreotide acetate, Dec., 761–810
analgesic effects of, Dec., 793–794
in autonomic neuropathy and hypotension, Dec., 794
behavioral effects of, Dec., 795–796
as cancer therapy, Dec., 784–788
in cirrhosis, Dec., 762–765
in dumping syndrome, Dec., 778–784

non-endocrine applications, Dec., 761–810
summary, Dec., 796–797
in pancreatic fistula, Dec., 770–778
in pancreatitis, acute, Dec., 770–778
in peptic ulcer disease, Dec., 765–770
in psoriasis, Dec., 790–793
in small bowel efflux, Dec., 788–790
tumor growth after, Dec., 786
in variceal bleeding, Dec., 762–765
Ocular complications: of inflammatory bowel disease, Nov., 704
Oculomotor palsies: supranuclear, after cephalic tetanus, Sept., 579
Ophthalmoplegic tetanus, Sept., 579
Orchiectomy: in prostate cancer, Apr., 252
Order: physician's, for respiratory care, June, 338
Organidin: in asthma, Jan., 42–43
Oscillation: high-frequency, June, 398
Osteoblastic vertebral metastasis: in prostate cancer, Apr., 231
Osteomyelitis: in inflammatory bowel disease, Nov., 704
Osteoporosis: and corticosteroids in asthma, Jan., 41
Otitis media: chronic, and cephalic tetanus, Sept., 579
Oxygen
in asthma, Jan., 14
blender, June, 369
hyperbaric, in Crohn's disease, Nov., 724
Oxyphenonium: in asthma, Jan., 37

P

Pacemaker: cardiac, in tetanus, Sept., 590
PAF: and bronchial hyperresponsiveness, Mar., 160
Palsy: supranuclear oculomotor, after cephalic tetanus, Sept., 579
Pancreas
cancer, somatostatin and octreotide in, Dec., 785–786
enzyme secretion, effect of somatostatin on, Dec., 772
exocrine function, somatostatin-related mechanisms inhibiting, Dec., 770
fistula, somatostatin and octreotide in, Dec., 770–778
Pancreatitis
acute, somatostatin and octreotide in, Dec., 770–778
after 5-ASA in inflammatory bowel disease, Nov., 717
Paprika splitter's lung, July, 456
Paralysis
diaphragmatic, in tetanus, Sept., 578
vocal cord, in tetanus, Sept., 578
Parenteral alimentation: in inflammatory bowel disease, Nov., 713–714
Parkinson's disease: somatostatin levels in, Dec., 796
Peak flow measurements: in asthma, Mar., 165–166
PEEP, June, 356–358
auto-, June, 401–402
generation
with exhalation diaphragm, spring-loaded, June, 359
with exhalation diaphragm, weighted, June, 360
with exhaled gas directed against opposing gas flow, June, 360
with tube under water, June, 359
pressure tracing of ventilator during, June, 358
system, typical face mask, June, 357
Pelvic lymph nodes (*see* Lymph nodes, pelvic)

D-Penicillamine: in progressive systemic sclerosis, Feb., 99
Penicillin: in tetanus, Sept., 588
Penicillium granuloma: presenting as solitary pulmonary nodule, May, 286
Peptic ulcer disease: somatostatin and octreotide in, Dec., 765–770
Perfusion: extracorporeal, for theophylline toxicity, Jan., 30
Pericarditis
  constrictive, Swan-Ganz catheterization in, Aug., 539, 540
  in inflammatory bowel disease, Nov., 704
Pets: and asthma, Jan., 22–23
Pharmacotherapy in asthma (*see* Asthma, drug therapy in)
Phentolamine: aerosolized, in asthma, Jan., 44
Phenylbutazone: causing pneumonitis, July, 459
Pheochromocytoma: tetanospasmin in study of, Sept., 575
Phosphate: in asthma, Jan., 18
Physical examination: in interstitial lung disease, Feb., 119
Physical therapy: in asthma, Jan., 15
Physician's order: for respiratory care, June, 338
Pigeon breeder's lung, July, 442–444
Pituitary
  adenoma, prolactin/growth hormone-producing, somatostatin and octreotide in, Dec., 785
  regulation of testosterone and adrenal androgen hormone synthesis, Apr., 251
  snuff taker's lung, July, 454–455
Plasma cell
  granulomas of lung, May, 287
  in hypersensitivity pneumonitis, July, 435
Plasmapheresis: in Goodpasture's syndrome, Feb., 114
Platelet-activating factor
  bronchial hyperresponsiveness and, Mar., 160
  in inflammatory bowel disease, Oct., 630
Pneumoconiosis: hard metal, July, 458–459
Pneumocystis carinii infection: presenting as solitary pulmonary nodules, May, 287
Pneumonia
  bronchiolitis obliterans-organizing, Feb., 81–84
    clinical features, Feb., 82–83
    diagnosis, Feb., 83
    histology, Feb., 82
    pathology, Feb., 82
    roentgenogram in, Feb., 83
    therapy, Feb., 84
  eosinophilic, chronic, Feb., 92–94
    clinical features, Feb., 93
    diagnosis, Feb., 94
    pathogenesis, Feb., 92
    pathology, Feb., 92
    roentgenogram in, Feb., 93
    therapy, Feb., 94
Pneumonitis
  granulomatous
    drug-induced, July, 459–460
    silicone-induced, July, 448
  hypersensitivity, Feb., 84–88; July, 419–471
    acute stage, clinical features, July, 430
    acute stage, histopathology, July, 422
    acute stage, radiologic findings, July, 431
    agents associated with, Feb., 86–87
    alveolitis mechanism in, July, 429
    antigenic material in, nature of, July, 421
    antigenic particle size in, July, 422
    bronchiolitis in, July, 424
    bronchoalveolar lavage in, July, 435–436
    causes, July, 438
    chronic stage, clinical features, July, 430
    chronic stage, histopathology, July, 425

chronic stage, radiologic findings, July, 431–432
clinical features, Feb., 87; July, 430
complement pathway activation in, alternate, July, 428
definition, July, 419–420
delayed hypersensitivity mechanisms in, July, 427–428
diagnosis, Feb., 87–88; July, 436–438
diagnosis, differential, July, 425, 432
electron microscopic features, July, 425
foreign body particles in, July, 424
fuel-chip induced, July, 449
granuloma formation in, July, 424
granuloma formation in, mechanism of, July, 429
histological features, July, 423, 424
histopathology, July, 422–425
history, July, 419
HLA associations in, July, 420–421
immune complex mechanisms in, July, 425, 427
immunologic reactivity of host and, July, 420
immunopathogenesis, July, 425–429
intensity of exposure and, July, 422
interstitial infiltration in, July, 424
intraalveolar buds in, July, 424
macrophages in, intraalveolar, July, 424
pathogenesis, Feb., 84–85
pathology, Feb., 84–85
P1 erythrocyte antigen in, July, 421
pulmonary function tests in, July, 433–434
radiographic features, July, 432
radiologic findings in, July, 431–433
risk factors, July, 420–422
skin tests in, July, 434–435
smoking and, July, 421
Sporobolomyces induced, July, 455
subacute stage, clinical features, July, 430
subacute stage, histopathology, July, 424
subacute stage, radiologic findings, July, 431
summer-type, July, 444–445
therapy, Feb., 88; July, 438–439
radiation, July, 459
Pneumothorax: after transthoracic needle biopsy of lung, May, 301
Pollen allergens: causing asthma, Jan., 23
Polyarthritis: in inflammatory bowel disease, Nov., 702
Polymyositis/dermatomyositis, interstitial lung disease in, Feb., 99–100
diagnosis, Feb., 100
therapy, Feb., 100
Polyneuropathy: inflammatory, after tetanus toxoid, Sept., 594
Polypeptide: vasoactive intestinal, in dumping syndrome, Dec., 780–781
P1 erythrocyte antigen: in hypersensitivity pneumonitis, July, 421
Portal venous pressure and flow: effect of somatostatin and octreotide on, Dec., 763–764
Positive end expiratory pressure (*see* PEEP)
Positive pressure
ventilation, high-frequency, June, 396–397
ventilator operating as controller, pressure curve for, June, 344
Potassium
chloride in asthma, Jan., 18
iodide
in asthma, Jan., 42–43
pneumonitis due to, July, 459

Potato riddler's lung, July, 457
Prazosin: inhaled, in asthma, Jan., 44
Precipitins: in hypersensitivity pneumonitis, July, 427
Prednisolone
in pulmonary fibrosis, idiopathic, Feb., 81
in tetanus, Sept., 587
Prednisone
in asthma, Jan., 18
in Churg-Strauss syndrome, Feb., 110
in Goodpasture's syndrome, Feb., 114–115
liquid, in pediatric asthma, Jan., 40
in granulomatosis
lymphomatoid, Feb., 112
Wegener's, Feb., 107
in lupus erythematosus, systemic, Feb., 102
in pneumonia
bronchiolitis obliterans-organizing, Feb., 84
eosinophilic, chronic, Feb., 94
in pneumonitis, hypersensitivity, Feb., 88
in polymyositis/dermatomyositis interstitial lung disease, Feb., 100
in pulmonary fibrosis, idiopathic, Feb., 80–81
in rheumatoid interstitial lung disease, Feb., 96
Pregnancy
asthma in, Jan., 25
theophylline and, Jan., 30
treatment, Jan., 44; Mar., 187–188
inflammatory bowel disease in, Nov., 695–696
Prelone: in pediatric asthma, Jan., 40
Pressure
airway (*see* Airway, pressure)
positive (*see* Positive pressure)
positive end expiratory (*see* PEEP)
support ventilation (*see* Ventilation, pressure support)
Pro-drugs: in asthma, Mar., 173
Prolactin
-producing pituitary adenoma, somatostatin and octreotide in, Dec., 785
serum, in prostate cancer, Apr., 210
Propofol: in tetanus, Sept., 589–590
Propranolol: in tetanus, Sept., 590
Prostate
anatomy, Apr., 213–214
biopsy, Apr., 217–218
after irradiation, external beam, Apr., 246
cancer (*see* Cancer, prostate)
endocrinology, Apr., 250–251
hypertrophy, benign, and prostate cancer, Apr., 212
intraepithelial neoplasia, Apr., 214–215
resection, transurethral, staging, Apr., 227–228
specific antigen in prostate cancer
for detection, Apr., 220–221
for staging, Apr., 226–227
ultrasound, transrectal, for cancer staging, Apr., 224–225
Prostatectomy, radical, for prostate cancer, Apr., 233–243
comparison to external beam irradiation, Apr., 247–248
after irradiation, external beam, complications of, Apr., 235
morbidity of, Apr., 234–238
after Walsh modifications, Apr., 237
prior to Walsh modifications, Apr., 236
mortality of, Apr., 234–238
after Walsh modifications, Apr., 237
prior to Walsh modifications, Apr., 236
patient selection for, Apr., 233–234
results, long-term, Apr., 243
surgical approach, Apr., 238
surgical technique, Apr., 238–243
survival after, Apr., 243

Proteinosis, pulmonary alveolar, Feb., 115–117
clinical features, Feb., 116
diagnosis, Feb., 117
pathogenesis, Feb., 115–116
pathology, Feb., 115–116
therapy, Feb., 117
Proventil: in asthma, Jan., 15
Pseudomonas aeruginosa lung abscess, May, 287
Pseudonodules: pulmonary, detection of, May, 282
Pseudotetanus, Sept., 583–584
Psoriasis: somatostatin and octreotide in, Dec., 790–793
Psychogenic contributions: in inflammatory bowel disease, Oct., 634–635
Psychological
factors in asthma, Jan., 26
problems, and tetanus, Sept., 584
Pulmonary
(*See also* Lung)
alveolar proteinosis (*see* Proteinosis, pulmonary alveolar)
amyloidosis, May, 289
angiography in solitary pulmonary nodules, May, 294
arteriovenous aneurysms, MRI of, May, 295
artery
catheter (*see* Catheter, pulmonary artery)
rupture after pulmonary artery catheterization, Aug., 502
bronchopulmonary aspergillosis, allergic, Mar., 153, 155
capillary wedge pressure with Swan-Ganz catheter, Aug., 521–522
respiration and, Aug., 523–524
carcinoids, May, 284–285
drug-induced granulomatous pneumonitis, July, 459–460
dysfunction in inflammatory bowel disease, Nov., 704
edema, noncardiac, Swan-Ganz catheterization in, Aug., 537
embolism, acute massive, Swan-Ganz catheterization in, Aug., 537, 538
fibrosis, idiopathic, Feb., 74–81
biopsy in, open, Feb., 76
clinical presentation, Feb., 77–79
diagnosis, Feb., 79–80
histologic features, Feb., 76
pathogenesis, Feb., 75–77
pathology, Feb., 75–77
roentgenogram in, Feb., 78
therapy, Feb., 80–81
function tests
in asthma, Jan., 14; Mar., 164–166
in interstitial lung disease, Feb., 123–124
in pneumonitis, hypersensitivity, July, 433–434
granuloma (*see* Granuloma, pulmonary)
histiocytosis X (*see* Histiocytosis X, primary pulmonary)
hypersensitivity, alginate, July, 457–458
hypertension
precapillary, chronic, Swan-Ganz catheterization in, Aug., 537
in sclerosis, progressive systemic, Feb., 97
infarct, May, 289
infiltrates, diffuse
(*See also* Lung, disease, interstitial)
chemicals associated with, Feb., 121
dusts associated with, inorganic, Feb., 120
injury, diffuse
(*See also* Lung, disease, interstitial)
drugs causing, Feb., 122
nodules, solitary, May, 279–318
angiography in, pulmonary, May, 294
benign, May, 285–289
biopsy in, May, 300–302
biopsy in, bronchoscopic, May, 300–301

Pulmonary *(cont.)*
biopsy in, transthoracic needle aspiration, May, 301–302
calcification patterns in, May, 286
decision analysis studies, May, 305–307
decision approaches to, quantitative, May, 304–307
definition, May, 279
detection, May, 280–282
DT of, relationship to probability of malignancy, May, 290–291
DT of, relationship to prognosis, May, 291
edges of, characteristic appearances, May, 288
evaluation, with biopsy procedures *(see* biopsy in *above)*
evaluation, clinical, May, 292–293
evaluation, by imaging techniques (*see* Imaging, of solitary pulmonary nodules)
fluoroscopy in, May, 294
granulomas presenting as, noninfectious, May, 287
growth rates in, May, 289–292
growth rates in, theoretical concepts, May, 290
historical aspects, May, 279–280
incidence, May, 279
malignant, May, 282–285
malignant, prevalence, May, 282–283
management, May, 307–310
management, algorithm for, May, 308
metastatic, May, 284
MRI of, May, 295
pCA in, calculation of, May, 304–305
resection, surgical risks in, May, 303
roentgenography in, chest (*see* Radiography, chest, in pulmonary nodules, solitary)
sputum cultures in, May, 300
sputum cytology in, May, 299–300
sputum examination in, May, 299–300
staging, pre-thoracotomy, May, 302–303
surgery for, May, 302–304
tomography in, computed (*see* Tomography, computed, of pulmonary nodules, solitary)
tomography in, conventional (*see* Tomography, conventional, of solitary pulmonary nodules)
"wait and watch" strategy in, May, 291–292
nodules in Wegener's granulomatosis, Feb., 105–106
pseudonodules, detection of, May, 282
vascular lesions, solitary, May, 289

R

Race: and prostate cancer, Apr., 211
Radiation
colitis, Nov., 710–711
diagnostic (*see* Radiography)
pneumonitis, July, 459
therapeutic (*see* Radiotherapy)
Radioallergosorbent test: in asthma, Mar., 171
Radiography, chest
in asthma, Jan., 14; Mar., 166–167
in Churg-Strauss syndrome, Feb., 109
in granulomatosis
lymphomatoid, Feb., 111
Wegener's, Feb., 105
in histiocytosis X, primary pulmonary, Feb., 91
in lung disease, interstitial, Feb., 119, 123
in pneumonia
bronchiolitis obliterans-organizing, Feb., 83
eosinophilic, chronic, Feb., 93
in pneumonitis, hypersensitivity, July, 432

in proteinosis, pulmonary alveolar, Feb., 116
in pulmonary fibrosis, idiopathic, Feb., 78
in pulmonary granulomatous diseases, July, 441
pulmonary infiltrate on, diffuse (*see* Lung, disease, interstitial)
in pulmonary nodules, solitary
for detection, May, 280–281
for evaluation, May, 294
in rheumatoid interstitial lung disease, Feb., 95
in sarcoidosis, July, 433
Radiology
in Crohn's disease, Nov., 688–689
in pneumonitis, hypersensitivity, July, 431–433
in ulcerative colitis, Nov., 684–685, 686, 687
Radiotherapy in prostate cancer, Apr., 244–249
external beam, Apr., 244–248
biopsy results after, Apr., 246
combined with interstitial irradiation, Apr., 249
comparison to radical prostatectomy, Apr., 247–248
complications, Apr., 245–246
morbidity of, Apr., 246
mortality of, Apr., 246
patient selection for, Apr., 244
prostatectomy after, radical, complications, Apr., 235
results, long-term, Apr., 246–247
survival after, Apr., 247
technique, Apr., 244–245
interstitial, Apr., 248–249
combined with external beam, Apr., 249
Ranitidine: vs. somatostatin and octreotide, in peptic ulcer disease, Dec., 769
RAST: in asthma, Mar., 171
Reagin-mediated asthma: ketotifen in, Jan., 38
Rectal
cancer (*see* Cancer, colorectal)
examination, digital, in prostate cancer
for detection, Apr., 217, 218–219, 221
for detection, comparison to transrectal ultrasound, Apr., 219
for staging, Apr., 224
Reflexes: spinal sympathetic, in tetanus, Sept., 574
Reflux: gastroesophageal, and asthma, Jan., 25
Renal sympathetic nerves: tetanus effects on, Sept., 574
Research tool: tetanospasmin as, Sept., 575
Resorcinols: in asthma, Mar., 173
Respiration: and pulmonary capillary wedge pressure with Swan-Ganz catheter, Aug., 523–524
Respiratory
care, physician's order for, June, 338
failure
causes, June, 334
identification, June, 333–336
muscle fatigue causing, June, 334–336
treatment, June, 333–339
muscle fatigue causing respiratory failure, June, 334–336
rate during asthma attack, Mar., 164
Retardation: developmental, after neonatal tetanus, Sept., 581
Retinoids: and prostate cancer, Apr., 212
Rhabdomyolysis: complicating tetanus, Sept., 591
Rheumatoid arthritis
lung disease in, interstitial, Feb., 95–96
diagnosis, Feb., 96
therapy, Feb., 96
solitary pulmonary nodules in, May, 287
Ribonucleic acid viruses: in prostate cancer, Apr., 212

Rifampin: in inflammatory bowel disease, Nov., 718
Risus sardonicus: in tetanus, Sept., 577
RNA viruses: in prostate cancer, Apr., 212
Roentgenography (*see* Radiography)
Rubber workers: prostate cancer among, Apr., 211
Rupture
  pulmonary artery, after pulmonary artery catheterization, Aug., 502
  ventricular septal, acute, Swan-Ganz catheterization in, Aug., 533, 536

S

Saligenins: in asthma, Mar., 173
Salmeterol: in asthma, Jan., 34
Sarcoidosis
  differences between extrinsic allergic alveolitis and, July, 442
  histologic features, July, 424
  roentgenographic diagnosis, July, 433
  solitary nodular, May, 287
Sarcoma: pulmonary, May, 285
Scanning
  (*See also* Imaging)
  bone, in prostate cancer, Apr., 232
  indium and technetium, in Crohn's disease, Nov., 689
Schizophrenia: somatostatin levels in, Dec., 796
School performance: and theophylline, Jan., 29
Sclerosing cholangitis: in inflammatory bowel disease, Nov., 703
Sclerosis
  multiple, somatostatin levels in, Dec., 796
  progressive systemic, interstitial lung disease in, Feb., 96–98
    diagnosis, Feb., 98
    therapy, Feb., 98
Secretin: effects of somatostatin and octreotide on, Dec., 772
Sedation: in asthma, Jan., 15
Sedatives: in inflammatory bowel disease, Nov., 715–717
Septal rupture: acute ventricular, Swan-Ganz catheterization in, Aug., 533, 536
Septic shock: Swan-Ganz catheterization in, Aug., 537
Serotonin: in dumping syndrome, Dec., 780
Sexually transmitted infectious agent: causing prostate cancer, Apr., 212
Shock: septic, Swan-Ganz catheterization in, Aug., 537
Short bowel syndrome: octreotide in, Dec., 790
SIADH: in tetanus, Sept., 574
Siemens Servo ventilator
  controls, June, 384–387
  gas flow diagram for, June, 382
  900B, June, 382–387
    control panel for, June, 384
    flow wave forms for, June, 385
    specifications for, June, 386
  900C, June, 382–394
    control panel for, June, 387
  900E, June, 382–387
  scissor valve, June, 383
Sigmoid volvulus: in inflammatory bowel disease, Nov., 704
Silicone induced granulomatous pneumonitis, July, 448
Sinusitis: and asthma, Jan., 24
Sisal worker's lung, July, 453
Skin tests: in hypersensitivity pneumonitis, July, 434–435
Sleep: somatostatin effects on, Dec., 795
Smallpox handler's lung, July, 457
Smoking
  histiocytosis X and, Feb., 89
  hypersensitivity pneumonitis and, July, 421
  inflammatory bowel disease and, Oct., 626–627
  pulmonary nodules and, solitary, May, 293
Snuff: pituitary snuff taker's lung, July, 454–455

Sodium bicarbonate: in asthma, Jan., 18
Solu-Medrol: in asthma, Jan., 18
Somatomedin-C: in psoriasis, Dec., 791–792
Somatostatin, Dec., 761–810
  action, proposed mechanisms of, Dec., 767
  analgesic effects of, Dec., 793–794
  analogue octreotide (*see* Octreotide acetate)
  in autonomic neuropathy and hypotension, Dec., 794
  behavioral effects of, Dec., 795–796
  as cancer therapy, Dec., 784–788
  in cirrhosis, Dec., 762–765
  in dumping syndrome, Dec., 778–784
  enzyme secretion in pancreas after, Dec., 772
  in inflammatory bowel disease, Nov., 725–726
  in neurologic disease etiology, Dec., 795
  non-endocrine applications, Dec., 761–810
    summary, Dec., 796–797
  in pancreatic fistula, Dec., 770–778
  in pancreatitis, acute, Dec., 770–778
  in peptic ulcer disease, Dec., 765–770
  in psoriasis, Dec., 790–793
  -related mechanisms inhibiting pancreatic exocrine function, Dec., 770
  -related splanchnic vasoconstriction, proposed mechanisms of action, Dec., 765
  in small bowel efflux, Dec., 788–790
  tumor growth after, Dec., 786
  in variceal bleeding, Dec., 762–765
Spasm: in tetanus, Sept., 578
Spätlese lung, July, 450
Spinal sympathetic reflexes: in tetanus, Sept., 574
Spirometer
  alarm on Bennett MA-1 ventilator, June, 380–381
  portable, in asthma, Mar., 164
Splanchnic vasoconstriction: somatostatin-related, proposed mechanisms of action, Dec., 765
Splenosis: intrathoracic, May, 289
Sporobolomyces induced hypersensitivity pneumonitis, July, 455
Sputum
  in asthma, Mar., 167–168
  cultures in solitary pulmonary nodules, May, 300
  cytology in solitary pulmonary nodules, May, 299–300
  examination in solitary pulmonary nodules, May, 299–300
Stain: gram, of culture of *Clostridium tetani*, Sept., 565
Steroids
  (*See also* Corticosteroids)
  in mixed connective tissue disease, Feb., 101
  in sclerosis, progressive systemic, Feb., 99
Stiff-man syndrome, Sept., 583
Stomach
  (*See also* Gastrointestinal)
  Crohn's disease of, Nov., 693–694
  emptying, effect of tetanus on, Sept., 574
Strictureplasty: in inflammatory bowel disease, Nov., 727
Strychnine intoxication: differentiated from tetanus, Sept., 582–583
Suberosis, July, 453
Substance-P: in psoriasis, Dec., 792
Sugar consumption: and inflammatory bowel disease, Nov., 712
Sulfamethoxazole (*see* Trimethoprim-sulfamethoxazole)
Sulfasalazine: in inflammatory bowel disease, Nov., 715–717
Summer-type hypersensitivity pneumonitis, July, 444–445

Supranuclear oculomotor palsies:
after cephalic tetanus, Sept., 579
Swan-Ganz catheter (*see* Catheter, Swan-Ganz)
Sympathetic
nerves, renal, tetanus effects on, Sept., 574
reflexes, spinal, in tetanus, Sept., 574
Sympathomimetics: in asthma, Jan., 15–16
Synaptic functions: tetanospasmin in study of, Sept., 575
Systemic defenses: in inflammatory bowel disease, Oct., 644–649

T

Tachyphylaxis: due to beta agonists in asthma, Jan., 33
Tamponade: acute cardiac, Swan-Ganz catheterization in, Aug., 537–538, 539
Technetium scanning: in Crohn's disease, Nov., 689
Terbutaline: in asthma, Jan., 15, 16
Terfenadine: in asthma, Jan., 37
Testosterone
hypothalamic pituitary regulation of, Apr., 251
levels, plasma, in prostate cancer, Apr., 210
Tetanospasmin
amino acid sequence of, Sept., 567
binding, internalization, and activity, steps in, Sept., 568
diffusion of, Sept., 570
fragments, various nomenclatures of, Sept., 566
as research tool, Sept., 575
synaptic activity, sites of, Sept., 572
Tetanus, Sept., 557–603
airway control in, Sept., 588
antibiotics in, Sept., 588
antispasticity agents in, Sept., 589–590
antitetanus immune status in, determination of, Sept., 584
autonomic nervous system effects of, Sept, 573–574
therapy, Sept., 590
central motor control effects of, Sept., 569–573
cephalic, Sept., 579, 580
complications, Sept., 591–592
corticosteroids in, Sept., 587
diagnostic approach, Sept., 581–584
differential diagnosis, Sept., 582
epidemiology, Sept., 561–563
etiology, Sept., 563–569
generalized, Sept., 576–578
management protocol for, Sept., 586–587
risus sardonicus in, Sept., 577
trismus in, Sept., 577
historical aspects, Sept., 559–561
immune globulin, human, Sept., 585, 587
local, Sept., 578
manifestations, Sept., 575–581
morbidity, Sept., 563
mortality, Sept., 563
neonatal, Sept., 579–581
neuromuscular junction blockade in, Sept., 590
neuromuscular junction effects of, Sept., 574–575
nutrition in, Sept., 591
pathogenesis, Sept., 569–575
pathophysiology, Sept., 569–575
portal of entry in, management, Sept., 585
prevention, Sept., 592–594
rating scale, Sept., 576
sketch of soldier with, Sir Charles Bell's, Sept., 560
therapy, Sept., 585–591
toxoid immunization, Sept., 592–594
adverse reactions to, Sept., 594
cephalic tetanus after, Sept., 579
after injury, Sept., 593–594
prophylactic, Sept., 592–593
ventilation control in, Sept., 588
Theophylline in asthma, Jan., 16–17, 28–30; Mar., 175–177
acute, Mar., 185

dosage, medications and conditions prompting change in, Jan., 29
measurement in bloodstream, Jan., 30
severe, Jan., 16–17
toxicity of, treatment, Jan., 30
Thrombocytosis: in inflammatory bowel disease, Nov., 704
Thrombosis: venous, in inflammatory bowel disease, Nov., 704
Thrush: due to corticosteroid aerosols in asthma, Jan., 35–36
Thymoxamine: aerosolized, in asthma, Jan., 43–44
Tidal volume generation
by compressing bellows, June, 340
by controlling gas delivery from compressed gas cylinder or wall outlet, June, 342
by manually squeezing gas-filled bag, June, 340
methods, ventilator classification by, June, 345–351
by piston pushing air from cylinder, June, 341
by unidirectional rapidly spinning valves, June, 341
Tire workers: prostate cancer among, Apr., 211
Tissue
connective (*see* Mixed connective tissue disease)
intestinal, abnormalities in inflammatory bowel disease, Oct., 627–632
T lymphocyte apheresis: in inflammatory bowel disease, Nov., 721
Tomography
computed
of carcinoids, pulmonary, May, 285
in lung disease, interstitial, Feb., 121
of pelvic nodes in prostate cancer, Apr., 229
in pneumonia, bronchiolitis obliterans-organizing, Feb., 83
in pneumonia, eosinophilic, chronic, Feb., 83
in pneumonitis, hypersensitivity, July, 432
in prostate cancer staging, Apr., 225
in pulmonary alveolar proteinosis, Feb., 116
of pulmonary nodules, solitary, for detection, May, 281–282
of pulmonary nodules, solitary, for evaluation, May, 295
in pulmonary nodules, solitary, for pre-thoracotomy staging, May, 302–303
of pulmonary nodules, solitary, showing Type 2 edge, May, 296
of pulmonary nodules, solitary, showing Type 3 edge, May, 297
of pulmonary nodules, solitary, showing Type 4 edge, May, 298
conventional, of solitary pulmonary nodules
for detection, May, 281–282
for evaluation, May, 294–295
Toxicity: theophylline, treatment of, Jan., 30
Tracheostomy: in tetanus, Sept., 588
Transfusions: in radical prostatectomy, Apr., 234
Transplantation
bowel, small, in inflammatory bowel disease, Nov., 727
liver, in inflammatory bowel disease, Nov., 725
Triamcinolone acetonide: in asthma, Jan., 35
Tricuspid regurgitation: Swan-Ganz catheterization in, Aug., 539, 541
Trimethoprim-sulfamethoxazole
in inflammatory bowel disease, Nov., 717
in Wegener's granulomatosis, Feb., 108

Trismus
in tetanus, Sept., 577
unilateral, due to brain stem tuberculoma, Sept., 583
Troleandomycin: in asthma, Jan., 45–46; Mar., 179
T-tube: intermittent, for weaning from mechanical ventilation, June, 400–401
Tuberculoma
brain stem, causing unilateral trismus, Sept., 583
pulmonary nodules due to, solitary, May, 285
Tuberculosis: intestinal, Nov., 709
Tumor
angiogenesis, effect of somatostatin and octreotide on, Dec., 788
carcinoid, pulmonary, May, 284–285
growth, effects of somatostatin and octreotide on, Dec., 786
lung (*see* Lung, tumors)
"Twinkling star" sign: differentiating pulmonary vessels from solitary nodules on CT, May, 282

U

Ulcer disease: peptic, somatostatin and octreotide in, Dec., 765–770
Ulcerative colitis, Nov., 682–685
(*See also* Inflammatory bowel disease)
discussion of, Oct., 649–651
distinctions and comparisons between Crohn's disease and, Nov., 693
endoscopy in, Nov., 684
pathology, Nov., 684
radiology in, Nov., 684–685, 686, 687
Ultrasound, transrectal, in prostate cancer
for detection, Apr., 218
comparison to digital rectal exam, Apr., 219
for staging, Apr., 224–225
Urinary incontinence: after radical prostatectomy, Apr., 234, 238

V

Vacuuming: and asthma, Jan., 21
Vanceril: in asthma, Jan., 35
Variceal bleeding: somatostatin and octreotide in, Dec., 762–765
Varicella: and corticosteroids in asthma, Jan., 41
Vascular
disease, collagen, associated with interstitial lung disease, Feb., 94
lesions, solitary pulmonary, May, 289
Vasoactive intestinal polypeptide: in dumping syndrome, Dec., 780–781
Vasoconstriction: somatostatin-related splanchnic, proposed mechanisms of action, Dec., 765
Vasointestinal peptide: in asthma, Mar., 160
Vasopressin: vs. somatostatin and octreotide in cirrhosis and variceal bleeding, Dec., 764–765
Vecuronium: in tetanus, Sept., 590
Vein
jugular, internal, cannulation method for Swan-Ganz catheterization, Aug., 516–517
portal, pressure and flow, effect of somatostatin and octreotide on, Dec., 763–764
thrombosis in inflammatory bowel disease, Nov., 704
Ventilation
airway pressure release, June, 365
control in tetanus, Sept., 588
high-frequency
benefits, potential, June, 399
definitions associated with, June, 396
disadvantages, June, 399
future, June, 399

gas flow during, augmented diffusion or enhanced diffusivity, June, 398
gas flow during, coaxial, June, 398
gas flow during, dynamics, June, 398
history, June, 395–396
jet, June, 397
oscillation, June, 398
positive pressure, June, 396–397
terms associated with, June, 396
intermittent mandatory
system, traditional, June, 362
ventilator controls and, June, 369
during weaning process, June, 401
mandatory minute, June, 365
mechanical, June, 331–406
in asthma, Jan., 20; Mar., 186
auto-PEEP during, June, 401–402
basics, June, 331–406
basis, June, 331–406
conclusions, June, 402–403
high-frequency (*see* Ventilation, high-frequency *above*)
historical perspective, June, 331–333
preparing patient for, June, 338–339
weaning from, June, 399–401
weaning from, cold turkey, June, 400
weaning from, criteria, June, 400
weaning from, intermittent mandatory ventilation during, June, 401
weaning from, intermittent T-tube for, June, 400–401
weaning from, pressure support ventilation during, June, 401
phases, June, 340–344
pressure support, June, 363–365
ventilator controls and, June, 369
during weaning process, June, 401
Ventilator(s)
alarms, June, 366–367
Bennett MA-1 (*see* Bennett MA-1 ventilator)
Bennett 7200 (*see* Bennett 7200 ventilator)
classification, June, 345–358
according to expiratory phase, June, 352–353
according to internal system by which tidal volume is delivered to patient, June, 353–354
according to mechanism for changing from inhalation to exhalation, June, 351–352
according to mechanism for cycling from exhalation to inhalation, June, 351
according to methods of generating tidal volume, June, 345–351
according to special functions, June, 354–358
classifying, June, 344–358
control(s), June, 367–369
CPAP, June, 368–369
I:E ratio, June, 368
intermittent mandatory ventilation, June, 369
mode, June, 367
normal pressure limit, June, 367–368
oxygen percentage, June, 369
PEEP, June, 368
respiratory rate, June, 367
sigh volume, June, 368
tidal volume, June, 367
wave form, June, 368
expiratory pressure pattern graphs, June, 353
first-generation, growth and development of, June, 332
high-frequency jet, gas flow through, June, 397
intermittent mandatory, June, 354
breathing pattern, typical, June, 355

Ventilator(s) *(cont.)*
synchronized, June, 354–355
monitors, June, 366–367
new generation *(see* third-generation *below)*
nonconventional, June, 395–399
oxygen blender on, June, 369
performance differences, basic, June, 344–345
positive pressure, operating as controller, pressure curve for, June, 344
pressure-cycled, June, 351–352
pressure curve generated during inspiration, June, 343
pressure tracing during PEEP, June, 358
second-generation, growth and development of, June, 332
Siemens Servo (*see* Siemens Servo ventilator)
third-generation, June, 381–395
growth and development of, June, 333
other, June, 395
time-cycled, June, 351
variables, June, 367–369
volume-cycled, June, 352
Ventolin: in asthma, Jan., 15
Ventricle
dysfunction, acute ischemic right, Swan-Ganz catheterization in, Aug., 532–533
septal rupture, acute, Swan-Ganz catheterization in, Aug., 533, 536
Vertebral metastasis: osteoblastic, in prostate cancer, Apr., 231
Videofluoroscopy: in cephalic tetanus, Sept., 579
Vineyard sprayer's lung, July, 453
VIPoma: somatostatin and octreotide in, Dec., 785
Virus
cytomegalovirus (*see* Cytomegalovirus)
immunodeficiency, human (*see* HIV infection)
infection and asthma, Jan., 24
RNA, in prostate cancer, Apr., 212
Vocal cord paralysis: in tetanus, Sept., 578
Volvulus: sigmoid, in inflammatory bowel disease, Nov., 704

W

Walsh technique: of radical prostatectomy, mortality and morbidity of, Apr., 237
Weaning
early, and infant vulnerability to inflammatory bowel disease, Oct., 644
from mechanical ventilation (*see* Ventilation, mechanical, weaning from)
Weevil: grain weevil disease, July, 456
Wegener's granulomatosis (*see* Granulomatosis, Wegener's)
Wheezing: differential diagnosis of, Mar., 164
Wood dust diseases, July, 452

X

X-rays (*see* Radiography)

Y

Yersinia ileitis, Nov., 709

Z

Zoladex: in prostate cancer, Apr., 252–253
Zollinger-Ellison syndrome: somatostatin and octreotide in, Dec., 768
Zymogen secretion: pancreatic, effect of somatostatin on, Dec., 775–776